Iovance Biotherapeutics Inc (NASDAQ: IOVA) stock suffered a major decline of -13.8% on 11/8/24. The shares closed at $10.59. Moreover, this decline was accompanied by exceptionally high trading volume at 480% of normal. The stock has risen 1.4% during the last week but has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, IOVA is expected to continue to be Value Creation neutral.
Iovance Biotherapeutics has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Iovance Biotherapeutics has a poor Power Rating of 23 and a very low Appreciation Score of 12, resulting in the Lowest Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment